<unk><unk>  is a fungus, recently described as a rare cause of fungal infection with significant resistance to antifungal medications. It was first described in the year 2009 in Japan, and since then, reports of C.<unk>  infection has been published from several countries. However, retrospective testing of collected isolates show the earliest known infection with C.<unk>  occurred in South Korea in 1996. Serious and prolonged outbreaks have been documented with data showing an innate resilience of C.<unk>  for survival, persistence in the clinical environment with the ability to rapidly colonize the skin of patients, and high transmissibility within the healthcare system. The first reported case in Europe involved over fifty cases in a span of more than sixteen months in a cardiothoracic center in London, and it is the largest outbreak in Europe. The precise mode of transmission within the healthcare facility is unknown. The high rate of therapeutic failure noted in cases of<unk><unk>  fungemia poses significant concerns. Misidentification of C.<unk>  with related<unk>  species such as<unk>  haemulonii by commercially available biochemical-based tests poses a challenge. C.<unk>  is recognized as a globally emerging fungal pathogen and it requires reproducible laboratory methods for identification and typing. Institution of key infection prevention and control measures, correct identification and standardized antifungal susceptibility testing for optimal management strategies of patients with invasive infections can hardly be overemphasized.
Candida auris infection
Baylisascaris infection
Dermatophytosis
Granulosis rubra nasi
Pseudomonas dermatitis
Herpes simplex anogenital infection
COVID-19-associated alopecia
Mycoplasma genitalium infection